Asunto(s)
Antineoplásicos/uso terapéutico , Proteínas en la Dieta/farmacología , Tiosemicarbazonas/uso terapéutico , Complejo Vitamínico B/farmacología , Animales , Carcinoma 256 de Walker/tratamiento farmacológico , Catarata/inducido químicamente , Dieta , Carbohidratos de la Dieta/farmacología , Masculino , Trasplante de Neoplasias , Ácido Pantoténico/farmacología , Ratas , Tiamina/farmacologíaAsunto(s)
Antineoplásicos/uso terapéutico , Carcinoma 256 de Walker/tratamiento farmacológico , Cobre/farmacología , Minerales/farmacología , Tiosemicarbazonas/uso terapéutico , Oligoelementos/farmacología , Animales , Antineoplásicos/toxicidad , Cobalto/farmacología , Dieta , Masculino , Trasplante de Neoplasias , Ratas , Tiosemicarbazonas/toxicidad , Zinc/farmacologíaAsunto(s)
Leucemia L1210/patología , Nucleósidos/toxicidad , Animales , Línea Celular , Cromatografía en Papel , Técnicas de Cultivo , ADN Nucleotidiltransferasas/antagonistas & inhibidores , ADN de Neoplasias/biosíntesis , Leucemia L1210/enzimología , Ratones , Trasplante de Neoplasias , Nucleósidos/análisis , Nucleótidos/metabolismo , Oxidorreductasas/antagonistas & inhibidores , Fosfotransferasas/antagonistas & inhibidores , ARN Neoplásico/biosíntesis , Timidina/análisis , Trasplante Homólogo , Tritio , Uridina/análisisAsunto(s)
Antígenos , Neoplasias , Fosfolípidos/análisis , Fosfolípidos/sangre , Animales , Reacciones Antígeno-Anticuerpo , Carcinoma 256 de Walker/inmunología , Carcinoma de Ehrlich/inmunología , Cromatografía en Papel , Glutamatos/análisis , Humanos , Leucemia Experimental , Hígado/análisis , Picratos/análisis , Ratas , Sarcoma Experimental , Espermina/análisis , Bazo/análisisAsunto(s)
Antineoplásicos/farmacología , Cicloparafinas/farmacología , Citarabina/farmacología , Leucemia L1210/tratamiento farmacológico , Animales , Antineoplásicos/administración & dosificación , Antineoplásicos/sangre , Antineoplásicos/metabolismo , Ácidos Carboxílicos/farmacología , Carcinoma de Células Escamosas , Línea Celular/efectos de los fármacos , Células Cultivadas/efectos de los fármacos , Citarabina/administración & dosificación , Citarabina/sangre , Citarabina/metabolismo , Citarabina/orina , ADN de Neoplasias/biosíntesis , Desaminación , Preparaciones de Acción Retardada , Depresión Química , Semivida , Haplorrinos , Humanos , Hidrólisis , Técnicas In Vitro , Leucemia L1210/metabolismo , Ratones , Proteínas de Neoplasias/biosíntesis , Fisostigmina , Plasma , ARN Neoplásico/biosíntesis , Tritio , UridinaRESUMEN
Mammalian cell culture systems were maintained free of mycoplasmas by using a 3-day agar plate test as a weekly routine to monitor the conditions of the cells. If contaminated cell cultures were found, they were discarded and replaced from a pleuropneumonia-like organism (PPLO)-free cell bank. PPLO-free lines were established by treatment with various antibiotics. The KB cell line was freed of mycoplasmas by treatment for 1 week with a mixture of chlortetracycline, kanamycin, and chloramphenicol. L-929 cells were cleared of contamination with either spectinomycin or tylosin, and a synovial cell line was cleared with lincomycin or tylosin. Each cell line, after eradication of the contaminant, was stored in liquid nitrogen. A number of agents were tested to determine minimal inhibitory concentration against three known and three unidentified mycoplasmas. Chlortetracycline and tetracycline were found to be highly active against all strains, whereas tylosin, spectinomycin, and lincomycin, though less active, were equally useful because of their low toxicity against cells. Kanamycin was highly active against three strains, but inactive at high levels against the KB cell contaminants. A disc plate test was used to check isolated cell contaminants for sensitivity to various agents.